The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Open accessPublished version of a preprint
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein 1-5 show promise therapeutically and are being evaluated clinically 6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs 9. Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The T478K mutation in the RBD is unique to the Delta variant and falls within the epitope region of potent neutralizing monoclonal antibodies categorized as 'Class1' 17”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Although circulating antibodies derived from plasma cells wane over time, long-lived immune memory can persist in expanded clones of memory B cells7,20.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“As seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less effective against pseudotyped viruses carrying the E484K mutation7,12,29.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [23]
In the citing paper
“Residue S477 is close to the receptor binding site (Fig ED2) and part of the epitope recognized by the S2E12 and C102 neutralizing antibodies 17,18 .”
From Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (2021) · cites this paper as [17]
In the citing paper
“a potent Ab that can recognize both “up” and “down” SARS-CoV-2 RBD conformations [41].”
From Deep geometric representations for modeling effects of mutations on protein-protein binding affinity (2021) · cites this paper as [41]
In the citing paper
“Importantly, our spike did not contain R346K, which has been observed at relatively low frequency (<10%) within the Omicron lineage, but which is known to mediate escape from class 3 neutralizing monoclonal antibodies such as AZD1061/cilgavimab (Barnes et al., 2020; Dong et al., 2021; Greaney et al., 2021b).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Cited by
Sorted by citations
Items 601–700 of 1,004
Bozdaganyan, M. E., Sokolova, O. S., Шайтан, К. В., Kirpichnikov, M. P., & Orekhov, P. S. (2022) · Viruses · doi:10.3390/v14020295 · Cited by 20
Liang, Z., Peng, T., Jiao, X., Zhao, Y. C., Xie, J., Jiang, Y., Meng, B., Fang, X. Z., Yu, X., & Dai, X. (2022) · Biosensors · doi:10.3390/bios12020103 · Cited by 22
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21
Cavani, M., Riofrío, W., & Arciniega, M. (2022) · Molecules · doi:10.3390/molecules27072370 · Cited by 23
Publication trends of research on COVID-19 and host immune response: A bibliometric analysis
Xia, Y. Q., Yao, R.-Q., Zhao, P., Tao, Z., Zheng, L., Zhou, H., Yao, Y.-M., & Song, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.939053 · Cited by 22
Wang, Y., Yan, A., Song, D., Dong, C., Rao, M., Gao, Y., Qi, R., Ma, X., Wang, Q., Xu, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00509-9 · Cited by 21
Predicting adaptive immune receptor specificities by machine learning is a data generation problem
Mason, D. M., & Reddy, S. T. (2024) · Cell Systems · doi:10.1016/j.cels.2024.11.008 · Cited by 19
SARS-CoV-2 spike conformation determines plasma neutralizing activityPreprint
Bowen, J. E., Walls, A. C., Joshi, A., Sprouse, K. R., Stewart, C., Tortorici, M. A., Franko, N., Logue, J. K., Mazzitelli, I. G., Tilles, S. W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473391 · Cited by 21
Bell, B. N., Powell, A. E., Rodríguez, C., Cochran, J. R., & Kim, P. S. (2021) · Protein Science · doi:10.1002/pro.4044 · Cited by 18
Kullappan, M., Mary, U., Ambrose, J. M., Veeraraghavan, V. P., & Surapaneni, K. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2014973 · Cited by 20
Sinha, S., Tam, B., & Wang, S. M. (2021) · Viruses · doi:10.3390/v14010001 · Cited by 22
Zhou, C., Qin, X., Yan, L., Jiang, Y., & Yu, X. (2022) · Infectious Medicine · doi:10.1016/j.imj.2021.08.001 · Cited by 21
Anwar, M. Z., Lodhi, M. S., Khan, M. T., Khan, M. I., & Sharif, S. (2022) · Genes · doi:10.3390/genes13030552 · Cited by 21
Nanoscopic Assessment of Anti-SARS-CoV-2 Spike Neutralizing Antibody Using High-Speed AFM
Lim, K., Nishide, G., Sajidah, E. S., Yamano, T., Qiu, Y., Yoshida, T., Kobayashi, A., Hazawa, M., Ando, T., Hanayama, R., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04270 · Cited by 20
Memory B cell development elicited by mRNA booster vaccinations in the elderly
Wang, Z., Muecksch, F., Raspe, R., Johannsen, F., Turroja, M., Canis, M., ElTanbouly, M. A., Santos, G. S. S., Johnson, B., Baharani, V. A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230668 · Cited by 19
Self-citationZhang, Y., Zhai, S., Huang, H., Qin, S., Sun, M., Chen, Y., Lan, X., Li, G.-H., Huang, Z., Wang, D., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02488-3 · Cited by 23
Kale, P. R., Gupta, E., Bihari, C., Patel, N., Rooge, S. B., Pandey, A. K., Bajpai, M., Khillan, V., Chattopadhyay, P., Devi, P., et al. (2021) · Vaccines · doi:10.3390/vaccines10010054 · Cited by 20
Du, W., Debski-Antoniak, O., Drabek, D., van Haperen, R., van Dortmondt, M., van der Lee, J., Drulyte, I., van Kuppeveld, F. J. M., Grosveld, F., Hurdiss, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49693-0 · Cited by 19
NMR Based SARS-CoV-2 Antibody Screening
Schoenle, M. V., Li, Y., Yuan, M., Clarkson, M. W., Wilson, I. A., Peti, W., & Page, R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03945 · Cited by 19
Rienzo, L. D., Monti, M. M., Milanetti, E., Miotto, M., Boffi, A., Tartaglia, G. G., & Ruocco, G. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.05.016 · Cited by 19
SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 19
Girl, P., Zwirglmaier, K., von Buttlar, H., Wölfel, R., & Müller, K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820151 · Cited by 19
Xue, J.-H., Wang, Y.-J., Li, W., Li, Q.-L., Xu, Q.-Y., Niu, J.-J., & Liu, L.-L. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0041-sa · Cited by 19
Frigerio, R., Marusic, C., Villani, M. E., Lico, C., Capodicasa, C., Andreano, E., Paciello, I., Rappuoli, R., Salzano, A. M., Scaloni, A., et al. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.956741 · Cited by 20
O’Kennedy, M. M., Abolnik, C., Smith, T., Motlou, T. P., Goosen, K., Sepotokele, K. M., Roth, R., du Preez, I., Truyts, A., Stark, H. C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.050 · Cited by 20
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Adams, L. J., VanBlargan, L. A., Liu, Z., Gilchuk, P., Zhao, H., Chen, R. E., Raju, S., Chong, Z., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 18
Protein Quality Control Systems and ER Stress as Key Players in SARS-CoV-2-Induced Neurodegeneration
Gavilán, E., Medina-Guzman, R., Bahatyrevich-Kharitonik, B., & Ruano, D. (2024) · Cells · doi:10.3390/cells13020123 · Cited by 20
Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
Cui, L., Li, T., Xue, W., Zhang, S., Wang, H., Liu, H., Gu, Y., Xia, N., & Li, S. (2024) · Viruses · doi:10.3390/v16060900 · Cited by 18
Lysine Β-Hydroxybutyrylation Improves Stability of COVID-19 Antibody
Li, Z., Zhang, Y., Han, M., Deng, H., Wu, F., Liu, G., & Chen, G. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01435 · Cited by 19
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
Moyo-Gwete, T., Madzivhandila, M., Mkhize, N. N., Kgagudi, P., Ayres, F., Lambson, B. E., Manamela, N. P., Richardson, S. I., Makhado, Z., van der Mescht, M. A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00558-22 · Cited by 18
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 26
McConnell, S. A., & Casadevall, A. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01150-9 · Cited by 27
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
Wang, F., Li, L., Dou, Y., Shi, R., Duan, X., Liu, H., Zhang, J., Liu, D., Wu, J., He, Y., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2032374 · Cited by 18
Kováčech, B., Fialová, Ľ., Filipčík, P., Škrabana, R., Žilková, M., Ivanovova, N. P., Kováč, A., Palova, D., Rolkova, G., Tomkova, K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103818 · Cited by 19
Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
Ju, B., Zhou, B., Song, S., Fan, Q., Ge, X., Wang, H., Cheng, L., Guo, H., Shu, D., Liu, L., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.732 · Cited by 17
Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection
Manuylov, V. A., Burgasova, O., Borisova, O. V., Васильевна, С. С., Vasina, D. V., Grigoriev, I. V., Kudryashova, A. M., Semashko, M. A., Сергеевич, Ч. Б., Сергеевна, Х. О., et al. (2022) · Viruses · doi:10.3390/v14030617 · Cited by 19
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 17
Targeting the SARS-CoV-2 HR1 with Small Molecules as Inhibitors of the Fusion Process
Gentile, D., Coco, A., Patamia, V., Zagni, C., Floresta, G., & Rescifina, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710067 · Cited by 19
Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents
Gelinas, A. D., Tan, T. K., Liu, S., Gilbert‐Jaramillo, J., Chadwick, J., Harding, A. C., Zhang, C., Ream, B. E., Chase, C. N., Otis, M. R., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.008 · Cited by 18
Delta-Omicron recombinant escapes therapeutic antibody neutralization
Duerr, R., Zhou, H., Tada, T., Dimartino, D., Marier, C., Zappile, P., Wang, G., Plitnick, J., Griesemer, S. B., Girardin, R. C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106075 · Cited by 18
Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication
Yu, D., Han, H.-J., Yu, J., Kim, J., Lee, G., Yang, J.-H., Song, B.-M., Tark, D., Choi, B., Kang, S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.018 · Cited by 18
Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
Zhang, F., Jenkins, J., de Carvalho, R. A., Nakandakari-Higa, S., Chen, T., Abernathy, M. E., Baharani, V. A., Nyakatura, E. K., Andrew, D. P., Lebedeva, I. V., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01389-9 · Cited by 21
Self-citationSARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses
Mo, C., Li, X., Wu, Q., Fan, Y., Liu, D., Zhu, Y., Yang, Y., Liao, X., Zhou, Z., Zhou, L., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.059 · Cited by 18
Sankhala, R. S., Dussupt, V., Chen, W., Bai, H., Martinez, E. J., Jensen, J. L., Rees, P. A., Hajduczki, A., Chang, W. C., Choe, M., et al. (2023) · Structure · doi:10.1016/j.str.2023.11.015 · Cited by 17
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Romero, J. A. A., Chingaté-López, S. M., Camacho, B., Alméciga-Díaz, C. J., & Ramirez-Segura, C. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26423 · Cited by 19
PTransIPs: Identification of Phosphorylation Sites Enhanced by Protein PLM Embeddings
Xu, Z., Zhong, H., He, B., Wang, X., & Lu, T. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3377362 · Cited by 18
Yin, R. M., Guest, J. D., Taherzadeh, G., Gowthaman, R., Mittra, I., Quackenbush, J., & Pierce, B. G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009380 · Cited by 18
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in micePreprint
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S., Kakutani, L. M., Keeffe, J. R., Wu, H.-J., Howarth, M. R., West, A. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.17.387092 · Cited by 19
Self-citationConserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike ProteinsPreprint
Wang, Z.-J., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H., Ramos, V. A., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · bioRxiv · doi:10.1101/2022.02.01.478695 · Cited by 20
Self-citationLuo, M., Zhou, R., Tang, B., Liu, H., Chen, B., Liu, N., Mo, Y., Zhang, P., Lee, Y. L., Ip, J. D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105354 · Cited by 17
Self-citationThe seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
Qin, X., Shen, J., Dai, E., Li, H., Tang, G., Zhang, L., Hou, X., Lu, M., Wu, X., Duan, S., et al. (2021) · BMC Immunology · doi:10.1186/s12865-021-00404-0 · Cited by 17
Structural biology in the time of COVID-19: perspectives on methods and milestones
Lynch, M. L., Snell, E. H., & Bowman, S. E. J. (2021) · IUCrJ · doi:10.1107/s2052252521003948 · Cited by 18
Sharma, D., Rawat, P., Vani, J., & Gromiha, M. M. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26277 · Cited by 17
Tang, H., Gao, L., Wu, Z., Meng, F., Zhao, X., Shao, Y., Hou, G., Du, X., & Qin, F. X.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836232 · Cited by 16
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062928 · Cited by 17
Bhattacharya, M., Chatterjee, S., Mallik, B., Sharma, A. R., & Chakraborty, C. (2022) · Vaccines · doi:10.3390/vaccines10101612 · Cited by 16
Mondeali, M., Etemadi, A., Barkhordari, K., Kesheh, M. M., Shavandi, S., Bahavar, A., Hosseini, F., Gomari, M. M., & Modarressi, M. H. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30367 · Cited by 15
SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity
Yu, S., Hu, H., Ai, Q., Bai, R., Ma, K., Zhou, M., & Wang, S. (2023) · Viruses · doi:10.3390/v15030639 · Cited by 20
Chi, X., Xia, L., Zhang, G., Chi, X., Huang, B., Zhang, Y., Chen, Z., Han, J., Wu, L., Li, Z., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00535-1 · Cited by 16
Kassardjian, A., Sun, E., Sookhoo, J. R. V., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112391 · Cited by 17
Egri, S. B., Wang, X., Díaz-Salinas, M. A., Luban, J., Dudkina, N. V., Munro, J. B., & Shen, K. (2023) · Nature Communications · doi:10.1038/s41467-023-38251-9 · Cited by 17
Modhiran, N., Lauer, S. M., Amarilla, A. A., Hewins, P., van den Broek, S. L., Low, Y. S., Thakur, N., Liang, B., Valenzuela, G., Jung, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107085 · Cited by 18
Banik, S. S. R., Kushnir, N., Doranz, B. J., & Chambers, R. (2023) · mAbs · doi:10.1080/19420862.2023.2273018 · Cited by 16
COVID-19 mutations: An overview
Sarkar, M. S., & Madabhavi, I. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i3.89761 · Cited by 22
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
Tian, S., Ji, K., Wang, M., Wang, F., Wang, H., Huang, W., Huang, Q., & Yan, J. (2021) · Cell Discovery · doi:10.1038/s41421-021-00331-9 · Cited by 16
Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Wang, F., Liu, L., Yuan, M., Ji, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202102181 · Cited by 20
Beddingfield, B. J., Maness, N. J., Fears, A. C., Rappaport, J., Aye, P. P., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., Blair, R. V., Carias, A. M., Madden, P. J., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.753444 · Cited by 15
Özger, Z. B., & Cihan, P. (2021) · Applied Soft Computing · doi:10.1016/j.asoc.2021.108280 · Cited by 17
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084376 · Cited by 18
Maghsood, F., Amiri, M. M., Zarnani, A., Salimi, V., Kardar, G. A., Khoshnoodi, J., Mobini, M., Zare, H. A., Ghaderi, A. A., Jeddi‐Tehrani, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.973036 · Cited by 17
Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein
Chen, Y., Lin, J.-J., Ma, H., Zhong, N., Xie, X.-X., Yang, Y., Zheng, P., Zhang, L., Jin, T., & Cao, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810904 · Cited by 18
Reduced B cell antigenicity of Omicron lowers host serologic response
Tubiana, J., Xiang, Y., Fan, L., Wolfson, H. J., Chen, K., Schneidman‐Duhovny, D., & Shi, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111512 · Cited by 18
Yang, Y., Wang, L., Liu, J., Fu, S., Zhou, L., & Wang, Y. (2022) · PubMed Central · doi:10.1097/md.0000000000028499 · Cited by 16
Analysis of the molecular mechanism of SARS-CoV-2 antibodies
Jin, D., Wei, J., & Sun, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.001 · Cited by 15
Amanat, F., Strohmeier, S., Lee, W.-H., Bangaru, S., Ward, A. B., Coughlan, L., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.01002-21 · Cited by 16
Bajpai, P., Singh, V., Chandele, A., & Kumar, S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.928279 · Cited by 16
Ling, Z., Yi, C., Sun, X., Yang, Z., & Sun, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2215-6 · Cited by 16
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
Streif, S., Neckermann, P., Spitzenberg, C., Weiß, K. T., Hoecherl, K., Kulikowski, K., Hahner, S., Nölting, C., Einhauser, S., Peterhoff, D., et al. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04548-3 · Cited by 17
Bhattacharya, M., Chatterjee, S., Lee, S., Dhama, K., & Chakraborty, C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101008 · Cited by 16
Adhikari, E. H., Lu, P., Kang, Y. J., McDonald, A. R., Pruszynski, J. E., Bates, T. A., McBride, S. K., Trank-Greene, M., Tafesse, F., & Lu, L. L. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad421 · Cited by 15
Lusvarghi, S., Stauft, C. B., Vassell, R. A., Williams, B., Baha, H., Wang, W., Neerukonda, S. N., Wang, T. T., & Weiss, C. D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011788 · Cited by 17
Gayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 17
Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15
Yang, Y., Wang, B., Li, W., Cai, H.-L., Qian, Q.-Y., Yu, Q. P., Shi, F., Bosch, B., & Huang, Y. (2024) · Journal of Virology · doi:10.1128/jvi.00139-24 · Cited by 15
Ives, C. M., Nguyen, L., Fogarty, C. A., Harbison, A. M., Durocher, Y., Klassen, J. S., & Fadda, E. (2024) · eLife · doi:10.7554/elife.95708 · Cited by 22
Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1
Yang, S., Yu, Y., Jian, F., Yisimayi, A., Song, W., Liu, J., Wang, P., Xu, Y., Wang, J., Niu, X., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2343909 · Cited by 15
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Asor, R., Olerinyova, A., Burnap, S. A., Kushwah, M. S., Soltermann, F., Rudden, L. S. P., Hensen, M., Vasiljević, S., Brun, J., Hill, M. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403260121 · Cited by 16
Rubio, A. A., Baharani, V. A., Dadonaite, B., Parada, M., Abernathy, M. E., Wang, Z., Lee, Y. E., Eso, M. R., Phung, J. L., Ramos, I., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5720 · Cited by 21
Self-citationVirus structure and structure-based antivirals
Plavec, Z., Pöhner, I., Poso, A., & Butcher, S. J. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.005 · Cited by 16
Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
Hendy, M. A., Kaufman, S., & Ponga, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01081-0 · Cited by 17
Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
Goyal, K., Goel, H., Baranwal, P., Tewary, A., Dixit, A., Pandey, A. K., Benjamin, M., Tanwar, P., Dey, A., Khan, F., et al. (2021) · Immuno · doi:10.3390/immuno1040032 · Cited by 15
Jugler, C., Sun, H., Nguyen, K., Palt, R., Felder, M., Steinkellner, H., & Chen, Q. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13970 · Cited by 16
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Almeida-Oliveira, A., Freire, D. P. B., de Andrade, A. R., Marques, A. D. M., Madeira, L. D. S., Senna, J. P. M., da Silveira, I. A. F. B., & Fialho, B. D. C. (2023) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-023-09713-w · Cited by 17
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19Preprint
Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.17.385500 · Cited by 16
Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccinationPreprint
Schaefer-Babajew, D. J., Wang, Z., Muecksch, F., Cho, A., Raspe, R., Johnson, B. A., Canis, M., DaSilva, J., Ramos, V., Turroja, M., et al. (2022) · medRxiv · doi:10.1101/2022.08.05.22278483 · Cited by 16
Self-citationSu, W.-Y., Du, P.-X., Santos, H. M., Ho, T.-S., Keskin, B. B., Pau, C. H., Yang, A.-M., Chou, Y.-Y., Shih, H.-C., & Syu, G. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05567 · Cited by 14
Metadata
- Authors
- Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Institute for Research in Biomedicine (CH)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2020-10-12
- Volume
- 588
- Issue
- 7839
- Pages
- 682-687
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8092461
- OpenAlex
- W3092403777
- Cited by
- 1,599
- References
- 70
- Citations by year
- 2026: 94 · 2025: 121 · 2024: 181 · 2023: 267 · 2022: 448 · 2021: 440 · 2020: 35
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-02)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy (P41GM103393, DE-AC02-)
- Burroughs Wellcome Fund
- George Mason University
- California Institute of Technology
- Wellcome Trust
- National Institutes of Health (AI138938, P01 AI138938-S1, AI150464)
- Office of Science (P41GM103393, DE-AC02)
- Beckman Institute, California Institute of Technology
- National Institute of General Medical Sciences (AI150464, P41GM103393)
- National Institute of Allergy and Infectious Diseases (P50AI150464, F30AI147579, P01AI138938)
- Basic Energy Sciences (DE-AC02, P41GM103393)
- Biological and Environmental Research (P41 GM103393)
- SLAC National Accelerator Laboratory (P41GM103393)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein receptor-binding domain, antibody-antigen complex structure, ACE2 receptor, epitope mapping, N-glycans, somatic hypermutation, antibody escape, avidity, antibody combination therapy, spike trimer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
